This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to Drexel University provides $210,867.00 to fund research on developing tolerogenic dendritic cell therapies to promote donor-specific immune tolerance for kidney transplant recipients.
The key products and services to be delivered under this grant include: 1) Engineering potent tolerogenic dendritic cells (TolDCs) containing microparticles loaded with a synergistic combination of tolerogenic drugs for sustained drug release; 2) Validating the ability of these "Push/Pull Particle TolDCs" to modulate dendritic cell phenotypes and influence donor-specific T regulatory responses; and 3) Exploring the potential of these engineered TolDCs to generate donor kidney tolerance when infused into donor kidneys prior to transplantation. This proof-of-concept study aims to advance a novel cell-based therapy to selectively suppress donor-specific immunity and improve outcomes for kidney transplant patients.
Generated 3/4/25, 8:14 AM